Reference : Le médicament du mois l'insuline «faster aspart» (Fiasp®)
Scientific journals : Article
Human health sciences : Pharmacy, pharmacology & toxicology
Human health sciences : Endocrinology, metabolism & nutrition
http://hdl.handle.net/2268/223516
Le médicament du mois l'insuline «faster aspart» (Fiasp®)
French
[en] Faster aspart insulin (fiasp®)
Paquot, Nicolas mailto [Université de Liège - ULiège > Département des sciences de la santé publique > Diabétologie, nutrition et maladies métaboliques >]
Scheen, André mailto [Université de Liège - ULiège > Département des sciences cliniques > Département des sciences cliniques >]
2018
Revue Médicale de Liège
73
4
211-215
Yes (verified by ORBi)
National
0370-629X
Belgium
[en] Prandial insulin ; Insulin pump ; Postprandial glycaemia ; Hypoglycaemia ; Insulin analogue ; Aspart insulin ; Insulin therapy ; Diabetes mellitus
[en] Fast-acting insulin aspart (faster aspart), commercialized under the trade name of Fiasp(R), is insulin aspart in a new formulation aiming to mimic the physiologic prandial insulin release more closely than currently available rapid-acting insulin products. Fiasp(R) is insulin aspart (NovoRapid(R)) in which two excipients (L-arginine and niacinamide) have been added, L-arginine serving as a stabilising agent, while niacinamide being responsible for accelerated initial absorption after subcutaneous administration. The pharmacokinetic characteristics of insulin faster aspart have the potential to better reproduce the fast endogenous prandial insulin secretion and thereby to improve postprandial glucose control compared with insulin aspart. The onset phase 3 programme compares head-to-head insulin faster aspart to insulin aspart. Studies showed significant reductions in postprandial glucose increment (in type 1 and type 2 diabetic patients), and glycated haemoglobin (HbA1C, in type 1 diabetes), without markedly increasing the risk of hypoglycaemia. A post hoc analysis of pooled data from six clinical trials conducted in patients with type 1 diabetes confirmed the beneficial pharmacokinetic and pharmacodynamic profiles of insulin faster aspart (earlier plasma insulin appearance, early insulin exposure two times greater and earlier offset of exposure of insulin faster aspart versus insulin aspart).
http://hdl.handle.net/2268/223516
https://www.rmlg.ulg.ac.be

File(s) associated to this reference

Fulltext file(s):

FileCommentaryVersionSizeAccess
Restricted access
201804_09.pdfPublisher postprint292.3 kBRequest copy

Bookmark and Share SFX Query

All documents in ORBi are protected by a user license.